Clinical trials: Grade III Obesity, open to volunteers
Obesity & Overweight
Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity
SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France.
- Trial name
- SEMAFOLLOW (NCT07423481)
- Testing
- SEMAFOLLOW questionnaire
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- Nantes University Hospital
Endometrial Cancer, Endometrial Cancer Stage I
SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer
SHAPE-ENDO is a single-center, open-label, pilot randomized clinical trial conducted at Hospital Universitari de Bellvitge in Barcelona, Spain.
- Conditions
- Endometrial Cancer, Endometrial Cancer Stage I, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I, Atypical Endometrial Hyperplasia
- Trial name
- SHAPE-ENDO (NCT07462663)
- Testing
- GLP-1 Receptor Agonist, Levonorgestrel IUD (Lng-IUD), Oral Progestins
- Volunteers
- 80 people
- Sponsor
- Hospital Universitari de Bellvitge